Search

Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer

FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

dose adjustments reduce the frequency and intensity of adverse

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

New agreement with Quallent expands biosimilar access

Boehringer Ingelheim enters private label agreement for biosimilar

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.

Express Scripts Adds BI Products to Roster | BI US

Read more on Express Scripts adding the Spiriva Respimat, Spiriva Handihaler and Stiolto Respimat to their commercial national preferred formulary.

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.

Clinical trials deliver medical breakthroughs – but how do they happen?

Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.

Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US

Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.

Boehringer inhalers now available at $35 a month for eligible patients

Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients

Deciphering Circuits in Neuroscience | Boehringer Ingelheim US

Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.

New affordability initiative with GoodRx for our biosimilar

Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar

Helping pets in hurricane-ravaged Puerto Rico

Our Partnering Approach in Animal Health

Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.

Our People, Our Culture

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers